O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results
- Resource Type
- Source
- Oral Abstracts.
- Subject
Oncology medicine.medical_specialty Bevacizumab business.industry Pembrolizumab Carboplatin chemistry.chemical_compound chemistry Internal medicine medicine Dose escalation business Metastatic cervical cancer medicine.drug - Language